Juniperus oxycedrus pollen allergens

The immune response to Juniperus oxycedrus allergens is a Type I hypersensitivity reaction initiated by exposure to pollen proteins from the Cade juniper tree. The primary molecular triggers are Jun o 1 (pectate lyase), Jun o 2 (thaumatin-like protein), and Jun o 4 (caleosin), which are recognized by the immune system in sensitized individuals (WHO/IUIS Allergen Nomenclature). Upon inhalation, these allergens bind to specific IgE antibodies on mast cells and basophils, triggering the release of inflammatory mediators like histamine and leukotrienes (PubMed: 11031332). This physiological cascade leads to the clinical manifestations of pollinosis, including allergic rhinitis, conjunctivitis, and potentially asthma, particularly in Mediterranean regions. Therapeutic intervention focuses on blocking the downstream effects of this response using H1-antihistamines and corticosteroids or modifying the immune system's sensitivity through allergen-specific immunotherapy (AIT) (StatPearls: Allergic Rhinitis). Because this target represents a complex biological process rather than a single receptor, drug development typically focuses on the inflammatory mediators or the specific allergenic proteins themselves.

Other names

Cade juniper allergensJuniperus oxycedrus pollinosisJun o allergensPrickly juniper allergens

Pharmacological management involves the antagonism of H1-histamine receptors to block mediator effects, agonism of glucocorticoid receptors to reduce inflammation, and the use of anti-IgE antibodies to prevent mast cell sensitization. Allergen-specific immunotherapy (AIT) aims to induce immunological tolerance by modulating T-cell responses and increasing IgG4 blocking antibodies.